WA melon-headed whale stranding investigation findings 'inconclusive'
The melon-headed whales were found by residents at Crab Creek, east of Broome and about 2,000 kilometres north of Perth, in January.
Melon-headed whales are small, toothed whales belonging to the oceanic dolphin family.
The Department of Biodiversity, Conservation and Attractions (DBCA) collected scientific information from the dead mammals to investigate the incident.
But it has since confirmed the cause of the stranding would remain unknown.
Marine scientist Holly Raudino said the species had only stranded twice previously in WA, so the incident was unusual and concerning.
She said research team members had done everything they could with the samples available.
"We hadn't anticipated how quickly the head and the soft tissues would decompose," she said.
"By the time we received the head, it appears that decomposition had already set in.
"We're always trying to improve on our efforts as much as we can and as funding permits."
Findings initially suggested the stranding was caused by intense noise, due to severe damage to the mammals' ears.
But because of significant decomposition, results regarding the ears were comprised and deemed inconclusive.
"Elsewhere in the world when this species is stranded, it's been suspected to be in relation to exposure to an intense noise source," Ms Raudino said.
The species is primarily found in deep water worldwide.
The whales travel in pods ranging from 100 to more than 1,000 members.
While the ultimate cause of the stranding is undetermined, Ms Raudino said the team's findings would help inform broader global understanding and research into strandings generally.
Envrions Kimberley executive director Martin Pritchard said the stranding had shocked residents.
He said it was disappointing the cause would not be fully understood.
"We have a world-class marine environment here and there's a responsibility on the government to make sure we know what's going on and to manage it properly," he said.
"We're a wealthy country; surely we've got the resources to monitor our marine life so we can understand what's been going on in our oceans."
Mr Pritchard said at the time of the incident there were reports of "very large noises" in the area cause by "pile drivers".
"We were concerned that could have had a direct impact on the whales," he said.
"Now we'll never know."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.
The Australian
a day ago
- The Australian
Patrick Star and 'Drag Queen' crab: underwater robot live stream captivates Argentines
A robot explores the dark, cold, deep sea floor of the South Atlantic, transmitting images of vibrant coral and fish never seen before as scientists give live commentary via YouTube. And Argentines can't get enough of it. The Argentine-American scientific mission is for the first time exploring the Mar del Plata canyon, a submarine gorge which plunges nearly 4,000 meters (13,000 feet) deep, off the coast of the seaside resort of the same name. The awed conversations between scientists leading the expedition and the explanations they give to viewers allow the public a rare insight into the hidden wonders of marine biology. In one instance, the camera on the SuBastian underwater robot shows a weird-looking, little white animal. One of the scientists on the team can be heard asking her colleagues, "Do we want it?" "Yes, yes, we want it!" reply dozens of messages in the live stream chat before the image shows the suction device being activated to suck up the specimen for study. "Oh, I love these little creatures," says one user. "I'm obsessed!" comments another. "Don't take the little one away!" pleads a third. The live stream began a week ago and exceeded one million views per day since Thursday, when it also began to be broadcast on television. "There are cold-water corals with the same colors as those in the Caribbean. How can that be? At a depth of 3,000 meters!" Pablo Penchaszadeh, a marine biologist and painter who is on board the expedition as an artist, told AFP. - Patrick Star - The 20-day expedition "Underwater Oases of the Mar del Plata Canyon" involves 25 scientists -- most of them from the Argentine research agency CONICET. Part of the GEMPA deep sea study group, with support from the US Schmidt Ocean Institute, it will end on August 10. Aboard the Schmidt Ocean Institute's "Falkor (too)" ship, scientists remotely operate the robot, which can descend to a depth of 4,500 meters (14,700 feet). They collect biological samples with its robotic arms and other instruments, and send back high-definition images. "The fact that anyone can connect from home and see what we are seeing live is a unique opportunity," explains expedition leader Daniel Lauretta in a statement. "Science is no longer something distant or inaccessible, but becomes part of everyday life." This week, social media users were delighted when an orange starfish with two symmetrical bumps resembling buttocks appeared on the live stream. It quickly prompted comparisons with Patrick Star, from the popular animated series SpongeBob SquarePants. Memes circulated joking that "Patrick is Argentine," marine biology became a trending topic on social media, and the broadcast reached the screens of hundreds of thousands of captivated viewers. "I came to see the big-bottomed star, is it here?" asked one user upon entering the YouTube chat. Spectators also gave other sea creatures nicknames: a king crab was dubbed "Drag Queen," and sea cucumber was fondly called "Sweet Potato." - 'Beacon of light' - This is the first time that human eyes -- albeit remotely -- have seen this underwater oasis in real time, where the cold, nutrient-rich Malvinas current and warm, salty Brazil current converge. The confluence is "one of the most energetic regions in our global Ocean," according to the website of the Schmidt Institute, with the temperature difference creating an area teeming with marine wildlife and flora. "We are already seeing incredible things: animals that have never been recorded in this area, underwater landscapes that look like something from another planet, and behaviors that surprise even the most experienced scientists," said Lauretta. But funding for such expeditions is under threat in Argentina. CONICET, the government's scientific research arm, has been severely underfunded by libertarian President Javier Milei, who has implemented draconian cuts to public spending with his infamous "chainsaw." Its budget fell by 21 percent last year, salaries have plummeted by 35 percent since the Milei took office in December 2023, and the cuts have led to an exodus of scientists. As a result, in between "oohs" and "aahs" of wonder, messages of support are flooding the live stream's chat: "Long live Conicet!". "Seeing people being passionate about their job is attractive," said Tomas Atilio Luppi, a biologist at the CONICET-affiliated marine and coastal research institute in Mar del Plata, who is not directly involved in the campaign. "This is happening at a very difficult time," he told AFP of the popular broadcast. "Science is in a very complicated position, both financially and in terms of support and human resources." "The fact that this craze is happening is like a beacon of light." bur-lm/dg/db/aks/st
ABC News
3 days ago
- ABC News
Shot-hole borer researchers team up against tree-killing beetle in Perth
Whether it is development, mining, or dwindling groundwater, Perth's tree canopy is facing a myriad of challenges. In addition, since 2021 the city has been struggling to contain a tree-killing invasive beetle — the polyphagous shot-hole borer. The pest, which produces a deadly fungus, mainly infects exotic trees, but native varieties like melaleucas are also at risk. To quell the spread of the beetle, the state government has to date removed 4,794 trees, some from Perth's most popular green spaces — Kings Park, Hyde Park and Stirling Gardens. Last month, a national biosecurity taskforce moved from an eradication response to long-term management, worrying many working in the space, particularly those in WA's agriculture sector. Teams of researchers are working on new methods to identify, contain and kill the beetle. Funded by the WA government through the WA Agriculture Research Centre (WAARC), three major projects have received $2.17 million, paying for three years of research. Key stakeholders met this week at a symposium to hear from the funding recipients about their research so far. Theo Evans, associate professor of applied entomology at the University of Western Australia, told the symposium two trials, which commenced in September 2024, showed very promising early results. He has been trialling two methods to combat the borer — a chemical injection into infected trees and using commercially available nematodes to eat the beetle. Treena Burgess, forest pathologist and director of the Harry Butler Institute, has been overseeing several studies at Murdoch University, most notably one into the fungus the beetle produces. "A key piece of our research is going to be trying to understand how susceptible different tree species are to the fungus," Professor Burgess said. "The beetle is the vector, and the fungus is the killer of trees, and different tree species seem to be varying considerably in their susceptibility." She said some trees responded better than others to the infection. Professor Burgess said the need for information on the beetle was so acute that the universities and stakeholders would share data as it came to hand, rather than waiting for the lengthy peer-review process. "The purpose of this is to solve the problem," she said. Managing director of environmental consultancy ArborCarbon and adjunct professor at Murdoch University Paul Barber will use funding to send up an "ArborCam" to map Perth's tree coverage. ArborCarbon has already led biosecurity responses in the eastern states. "The ArborCam is special because it can collect 11 bands of data across the spectrum, and it measures things like the condition of vegetation, height, surface temperatures," Professor Barber said. ArborCarbon will use the technology to identify where the most susceptible trees are, to focus on-the-ground efforts. Professor Barber said the goal was to make the ArborCam data available online for stakeholders and researchers. Ben Phillips, professor of population biology at Curtin University, is creating models to understand how the shot-hole borer might spread, and measure how effective current methods of detection are. He has taken information from dozens of studies to create a model of population growth, and his team has discovered population growth is dependent on temperature. "Most of the eastern seaboard of Queensland is looking like a spot for the borer, particularly the area around Cairns." He said considering Perth did not even have the ideal climate, the beetle had an incredibly high growth rate. The female borer does not require a male to reproduce, and Professor Phillip's modelling showed the population could grow in Perth conditions from one to a million in just a year. All the researchers the ABC spoke to were optimistic their efforts would lead to better management tools for the dreaded pest.
